Mineral Content and Antisickling Activity of Annona senegalensis, Alchornea cordifolia and Vigna unguiculata Used in the Management of Sickle Cell Disease in the Kwilu Province (Congo, DR)

Aims: To determine the mineral composition of some plants (Annona senegalensis Pers., Alchornea cordifolia (Schumach. & Thonn.) Müll. Arg. and Vigna unguiculate (L.) Walp.) used in the management of sickle cell disease by traditional practitioners in Kwilu province and to evaluate their antisickling activity in vitro. Study Design: Plant collection in the Kwilu province, sample preparation, antisickling tests and fluorescence spectrometric analysis. Place and Duration of Study: This work was performed at the Faculty of Science, University of Kinshasa, Congo DR, from October 2016 to January 2018. Methodology: These three plants were harvested in the province of Kwilu in Democratic Republic of the Congo. The mineral composition analysis was carried out using the fluorescence spectrometric method while the in vitro antisickling activity was evaluate using Emmel and hemolysis tests. Results: Twenty three mineral elements were identified in each of these three plants: Potassium (K), Phosphorus (P), Calcium (Ca), Sodium (Na), Magnesium (Mg), Sulphur (S), Chlorine (Cl) and trace elements as: Aluminum (Al), Silicon (Si), Vanadium (V), Chromium (Cr), Manganese (Mn), Iron (Fe), Nickel (Ni), Copper (Cu), Zinc (Zn), Selenium (Se), Brome (Br), Molybdenum (Mo), Tin (Sn), Iodine (I), Barium (Ba) and Lead (Pb). Annona senegalensis Pers., Alchornea cordifolia (Schumach. & Thonn.) Müll.Arg. and Vigna unguiculate (L.) Walp. aqueous extracts showed the capacity to prevent the sickling and the hemolysis of red blood cells. Conclusion: The obtained results confirm the antisickling activity thus justifying the use of these plants in Traditional Medicine for the management of sickle cell disease. The presence of some mineral elements like Fe, Zn, Mg and Se are useful for sickle cell disease patients.

Download Full-text

Mineral Composition of Medicinal Plants Traditionally Used in the Management of Sickle Cell Disease in the Kwilu Province (Congo-Kinshasa)

Sumerianz Journal of Biotechnology ◽

10.47752/sjb.41.16.21 ◽

2021 ◽

pp. 16-21

Author(s):

J. M. Kitadi ◽

C. L. Inkoto ◽

E. M. Lengbiye ◽

D. S. T. Tshibangu ◽

D. D. Tshilanda ◽

...

Keyword(s):

Sickle Cell Disease ◽

Mineral Composition ◽

Sickle Cell ◽

Democratic Republic Of Congo ◽

Correlation Coefficients ◽

Mineral Elements ◽

Spectrometric Method ◽

Spectrometric Analysis ◽

Composition Analysis ◽

Cell Disease

The aim of this study was to determine the mineral composition of 10 plants especially Alchornea cordifolia, Alternanthera bettzickiana, Annona senegalensis, Cyttaranthus congolensis, Dissotis brazzae, Justicia secunda, Harungana madagascariensis, Hura crepitans, Hypoxis angustifolia and Vigna unguiculata used in the management of sickle cell disease by traditional practitioners in Kwilu Province. The Plants collection was done at Kwilu province, sample were evaluated through fluorescence spectrometric analysis. These plants were harvested in Kwilu province in the Democratic Republic of Congo The mineral composition analysis was carried out using the fluorescence spectrometric method. This study revealed presence of Twenty-three (23) mineral elements, in each of these plants among others: Potassium (K), Phosphorus (P), Calcium (Ca), Sodium (Na), Magnesium (Mg), Sulphur (S), Chlorine (Cl) and trace elements such as: Aluminum (Al), Silicon (Si), Vanadium (V), Chromium (Cr), Manganese (Mn), Iron (Fe), Nickel (Ni), Copper (Cu), Zinc (Zn), Selenium (Se), Bromine (Br), Molybdenum (Mo), Tin (Sn), Iodine (I), Barium (Ba) and Lead (Pb). Iron, Zinc (Zn), Selenium (Se), Copper (Cu), Calcium (Ca), Magnesium (Mg) and Manganese (Mn) are mineral elements that are related to sickle cell disease. Of all these elements, Potassium and Calcium were in a higher content while Lead, Tin, Bromine, Copper and Nickel are in trace amounts. The correlation coefficients obtained between the mineral elements are significant. The presence of some mineral elements like Fe, Zn, mg and Se can be useful for sickle cell disease patients.

Download Full-text

Hypoxia-induced acute lung injury in murine models of sickle cell disease

AJP Lung Cellular and Molecular Physiology ◽

10.1152/ajplung.00288.2002 ◽

2004 ◽

Vol 286 (4) ◽

pp. L705-L714 ◽

Cited By ~ 57

Author(s):

Kirkwood A. Pritchard ◽

Jingsong Ou ◽

Zhijun Ou ◽

Yang Shi ◽

James P. Franciosi ◽

...

Keyword(s):

Sickle Cell Disease ◽

Lung Injury ◽

Sickle Cell ◽

Globin Gene ◽

Heat Shock Protein 90 ◽

Cell Disease ◽

Vascular Congestion ◽

Nitrite Nitrate ◽

Endothelial Nitric Oxide

Vaso-occlusive events are the major source of morbidity and mortality in sickle cell disease (SCD); however, the pathogenic mechanisms driving these events remain unclear. Using hypoxia to induce pulmonary injury, we investigated mechanisms by which sickle hemoglobin increases susceptibility to lung injury in a murine model of SCD, where mice either exclusively express the human α/sickle β-globin (hαβS) transgene (SCD mice) or are heterozygous for the normal murine β-globin gene and express the hαβStransgene (mβ+/-, hαβS+/-; heterozygote SCD mice). Under normoxia, lungs from the SCD mice contained higher levels of xanthine oxidase (XO), nitrotyrosine, and cGMP than controls (C57BL/6 mice). Hypoxia increased XO and nitrotyrosine and decreased cGMP content in the lungs of all mice. After hypoxia, vascular congestion was increased in lungs with a greater content of XO and nitrotyrosine. Under normoxia, the association of heat shock protein 90 (HSP90) with endothelial nitric oxide synthase (eNOS) in lungs of SCD and heterozygote SCD mice was decreased compared with the levels of association in lungs of controls. Hypoxia further decreased association of HSP90 with eNOS in lungs of SCD and heterozygote SCD mice, but not in the control lungs. Pretreatment of rat pulmonary microvascular endothelial cells in vitro with xanthine/XO decreased A-23187-stimulated nitrite + nitrate production and HSP90 interactions with eNOS. These data support the hypotheses that hypoxia increases XO release from ischemic tissues and that the local increase in XO-induced oxidative stress can then inhibit HSP90 interactions with eNOS, decreasing ·NO generation and predisposing the lung to vaso-occlusion.

Download Full-text

Endothelial Barrier Integrity Is Disrupted In Vitro by Heme and by Serum From Sickle Cell Disease Patients

Frontiers in Immunology ◽

10.3389/fimmu.2020.535147 ◽

2020 ◽

Vol 11 ◽

Author(s):

Vanessa Araujo Gomes Santaterra ◽

Maiara Marx Luz Fiusa ◽

Bidossessi Wilfried Hounkpe ◽

Francine Chenou ◽

Wouitchekpo Vincent Tonasse ◽

...

Keyword(s):

Sickle Cell Disease ◽

Healthy Volunteers ◽

Sickle Cell ◽

Endothelial Barrier ◽

Acute Chest Syndrome ◽

Cell Disease ◽

Experimental Conditions ◽

Cell Monolayers ◽

Junction Protein

Free extracellular heme has been shown to activate several compartments of innate immunity, acting as a danger-associated molecular pattern (DAMP) in hemolytic diseases. Although localized endothelial barrier (EB) disruption is an important part of inflammation that allows circulating leukocytes to reach inflamed tissues, non-localized/deregulated disruption of the EB can lead to widespread microvascular hyperpermeability and secondary tissue damage. In mouse models of sickle cell disease (SCD), EB disruption has been associated with the development of a form of acute lung injury that closely resembles acute chest syndrome (ACS), and that can be elicited by acute heme infusion. Here we explored the effect of heme on EB integrity using human endothelial cell monolayers, in experimental conditions that include elements that more closely resemble in vivo conditions. EB integrity was assessed by electric cell-substrate impedance sensing in the presence of varying concentrations of heme and sera from SCD patients or healthy volunteers. Heme caused a dose-dependent decrease of the electrical resistance of cell monolayers, consistent with EB disruption, which was confirmed by staining of junction protein VE-cadherin. In addition, sera from SCD patients, but not from healthy volunteers, were also capable to induce EB disruption. Interestingly, these effects were not associated with total heme levels in serum. However, when heme was added to sera from SCD patients, but not from healthy volunteers, EB disruption could be elicited, and this effect was associated with hemopexin serum levels. Together our in vitro studies provide additional support to the concept of heme as a DAMP in hemolytic conditions.

Download Full-text

The gut microbiome in sickle cell disease: Characterization and potential implications

PLoS ONE ◽

10.1371/journal.pone.0255956 ◽

2021 ◽

Vol 16 (8) ◽

pp. e0255956

Author(s):

Hassan Brim ◽

James Taylor ◽

Muneer Abbas ◽

Kimberly Vilmenay ◽

Mohammad Daremipouran ◽

...

Keyword(s):

Sickle Cell Disease ◽

Sickle Cell ◽

Gut Microbiome ◽

Tissue Injury ◽

Organ Damage ◽

Composition Analysis ◽

Cell Disease ◽

Blood Disorder ◽

Major Player ◽

Next Generation Sequencing Ngs

Background Sickle Cell Disease (SCD) is an inherited blood disorder that leads to hemolytic anemia, pain, organ damage and early mortality. It is characterized by polymerized deoxygenated hemoglobin, rigid sickle red blood cells and vaso-occlusive crises (VOC). Recurrent hypoxia-reperfusion injury in the gut of SCD patients could increase tissue injury, permeability, and bacterial translocation. In this context, the gut microbiome, a major player in health and disease, might have significant impact. This study sought to characterize the gut microbiome in SCD. Methods Stool and saliva samples were collected from healthy controls (n = 14) and SCD subjects (n = 14). Stool samples were also collected from humanized SCD murine models including Berk, Townes and corresponding control mice. Amplified 16S rDNA was used for bacterial composition analysis using Next Generation Sequencing (NGS). Pairwise group analyses established differential bacterial groups at many taxonomy levels. Bacterial group abundance and differentials were established using DeSeq software. Results A major dysbiosis was observed in SCD patients. The Firmicutes/Bacteroidetes ratio was lower in these patients. The following bacterial families were more abundant in SCD patients: Acetobacteraceae, Acidaminococcaceae, Candidatus Saccharibacteria, Peptostreptococcaceae, Bifidobacteriaceae, Veillonellaceae, Actinomycetaceae, Clostridiales, Bacteroidacbactereae and Fusobacteriaceae. This dysbiosis translated into 420 different operational taxonomic units (OTUs). Townes SCD mice also displayed gut microbiome dysbiosis as seen in human SCD. Conclusion A major dysbiosis was observed in SCD patients for bacteria that are known strong pro-inflammatory triggers. The Townes mouse showed dysbiosis as well and might serve as a good model to study gut microbiome modulation and its impact on SCD pathophysiology.

Download Full-text

In vivo survival studies of 51Cr-labeled methyl acetimidate treated erythrocytes in patients with sickle cell disease

Blood ◽

10.1182/blood.v56.6.1041.1041 ◽

1980 ◽

Vol 56 (6) ◽

pp. 1041-1047 ◽

Cited By ~ 5

Author(s):

TG Gabuzda ◽

TL Chao ◽

MR Berenfeld ◽

T Gelbart

Keyword(s):

Sickle Cell Disease ◽

Survival Time ◽

Sickle Cell ◽

Clinical Testing ◽

Cell Disease ◽

Show Evidence ◽

Survival Studies ◽

Circulating Antibody

Abstract Studies of the survival time of 51Cr labeled erythrocytes treated in vitro with methyl acetimidate (MAI) were conducted in 13 patients with sickle cell disease in order to assess the suitability of this antisickling agent for more extensive clinical testing. In comparison with previously measured control values (average t1/2 8.4 +/- 1.1 days a), the survival time of the treated erythrocytes in 10 of the patients who were not transfused was initially prolonged (average t1/2 24.4 +/- 4.6 days). However, 5 of the 13 patients studied developed circulating antibody against the MAI treated erythrocytes, markedly reducing the survival time of MAI treated erythrocytes in subsequent studies. Two patients, each challenged 3 times with infused MAI treated erythrocytes, failed to show evidence of antibody production, suggesting that not all subjects become immunized even after repeated exposure. In spite of many other promising properties of MAI as an antisickling agent of potential value, consideration of its use in further clinical testing must depend on successful avoidance of immunization in patients receiving infusions of treated erythrocytes.

Download Full-text

Placenta growth factor in sickle cell disease: association with hemolysis and inflammation

Blood ◽

10.1182/blood-2009-04-217950 ◽

2010 ◽

Vol 115 (10) ◽

pp. 2014-2020 ◽

Cited By ~ 35

Author(s):

Julia E. Brittain ◽

Ben Hulkower ◽

Susan K. Jones ◽

Dell Strayhorn ◽

Laura De Castro ◽

...

Keyword(s):

Growth Factor ◽

Sickle Cell Disease ◽

Sickle Cell ◽

Predictive Accuracy ◽

Cross Sectional Study ◽

Acute Chest Syndrome ◽

Cell Disease ◽

Placenta Growth Factor ◽

Cross Sectional

Abstract Placenta growth factor (PlGF) is released by immature erythrocytes and is elevated in sickle cell disease (SCD). Previous data generated in vitro suggest that PlGF may play a role in the pathophysiology of SCD-associated pulmonary hypertension (PHT) by inducing the release of the vasoconstrictor, endothelin-1. In this cross-sectional study of 74 patients with SCD, we confirm that PlGF is significantly elevated in SCD compared with healthy control subjects. We found significantly higher levels of PlGF in SCD patients with PHT but observed no association of PlGF with the frequency of acute pain episodes or history of acute chest syndrome. The observed correlation between PlGF and various measures of red cell destruction suggests that hemolysis, and the resultant erythropoietic response, results in the up-regulation of PlGF. Although relatively specific, PlGF, as well as N-terminal pro-brain natriuretic peptide and soluble vascular cell adhesion molecule, has low predictive accuracy for the presence of PHT. Prospective studies are required to conclusively define the contribution of PlGF to the pathogenesis of PHT and other hemolytic complications in SCD.

Download Full-text

Students’ knowledge on sickle cell disease in Kisangani, Democratic Republic of the Congo

Hematology ◽

10.1080/16078454.2020.1727174 ◽

2020 ◽

Vol 25 (1) ◽

pp. 91-94 ◽

Cited By ~ 1

Author(s):

Paul Kambale-Kombi ◽

Roland Marini Djang’eing’a ◽

Jean-Pierre Alworong’a Opara ◽

Serge Tonen-Wolyec ◽

Charles Kayembe Tshilumba ◽

...

Keyword(s):

Sickle Cell Disease ◽

Sickle Cell ◽

Democratic Republic ◽

Cell Disease ◽

Republic Of The Congo

Download Full-text

Voxelotor Treatment Interferes With Quantitative and Qualitative Hemoglobin Variant Analysis in Multiple Sickle Cell Disease Genotypes

American Journal of Clinical Pathology ◽

10.1093/ajcp/aqaa067 ◽

2020 ◽

Vol 154 (5) ◽

pp. 627-634

Author(s):

Nicola J Rutherford-Parker ◽

Sean T Campbell ◽

Jennifer M Colby ◽

Zahra Shajani-Yi

Keyword(s):

Sickle Cell Disease ◽

Sickle Cell ◽

High Performance ◽

Clinical Laboratory ◽

The United States ◽

Cell Disease ◽

Hemoglobin Variant ◽

Hbd Punjab ◽

The Impact

Abstract Objectives Voxelotor was recently approved for use in the United States as a treatment for sickle cell disease (SCD) and has been shown to interfere with the quantitation of hemoglobin (Hb) S percentage. This study aimed to determine the effect of voxelotor on the quantitation of hemoglobin variant levels in patients with multiple SCD genotypes. Methods In vitro experiments were performed to assess the impact of voxelotor treatment on hemoglobin variant testing. Whole blood samples were incubated with voxelotor and then analyzed by routinely used quantitative and qualitative clinical laboratory methods (high-performance liquid chromatography [HPLC], capillary zone electrophoresis [CZE], and acid and alkaline electrophoresis). Results Voxelotor modified the α-globin chain of multiple hemoglobins, including HbA, HbS, HbC, HbD-Punjab, HbE, HbA2, and HbF. These voxelotor-hemoglobin complexes prevented accurate quantitation of multiple hemoglobin species, including HbS, by HPLC and CZE. Conclusions Technical limitations in quantifying HbS percentage may preclude the use of HPLC or CZE for monitoring patients treated with voxelotor. Furthermore, it is unclear whether HbS-voxelotor complexes are clinically equivalent to HbS. Consensus guidelines for reporting hemoglobin variant percentages for patients taking voxelotor are needed, as these values are necessary for determining the number of RBC units to exchange in acute situations.

Download Full-text